RapidAIM: A culture- and metaproteomics-based Rapid Assay of Individual Microbiome responses to drugs
Background Human-targeted drugs may exert off-target effects on the gut microbiota. However, our understanding of such effects is limited due to a lack of rapid and scalable assay to comprehensively assess microbiome responses to drugs. Drugs can drastically change the overall microbiome abundance, microbial composition and functions of a gut microbiome. Although we could comprehensively observe these microbiome responses using a series of tests, for the purpose of a drug screening, it is important to decrease the number of analytical tools used. Results Here, we developed an approach to screen compounds against individual microbiomes in vitro using metaproteomics adapted for both absolute bacterial abundances and functional profiling of the microbiome. Our approach was evaluated by testing 43 compounds (including four antibiotics) against five individual microbiomes. The method generated technically highly reproducible readouts, including changes of overall microbiome abundance, microbiome composition and functional pathways. Results show that besides the antibiotics, compounds berberine and ibuprofen inhibited the accumulation of biomass during in vitro growth of the microbiome. By comparing genus and species level-biomass contributions, selective antibacterial-like activities were found with 36 of the 39 non-antibiotic compounds. Seven of our compounds led to a global alteration of the metaproteome, with apparent compound-specific patterns of functional responses. The taxonomic distributions of responded proteins varied among drugs, i.e. different drugs affect functions of different members of the microbiome. We also showed that bacterial function can shift in response to drugs without a change in the abundance of the bacteria. Conclusions Current drug-microbiome interaction studies largely focus on relative microbiome composition and microbial drug metabolism. In contrast, our workflow enables multiple insights into microbiome absolute abundance and functional responses to drugs using metaproteomics as the one-stop screening tool. The workflow is robust, reproducible and quantitative, and is scalable for personalized high-throughput drug screening applications. * COG : Clusters of orthologous groups DMSO : Dimethyl sulfoxide FDR : False-discovery rate FOS : Fructooligosaccharide GABA : Gamma-Aminobutyric Acid KEGG : Kyoto Encyclopedia of Genes and Genomes LC-MS/MS : Liquid chromatography–tandem mass spectrometry LFQ : Label-free quantification NSAIDs : Nonsteroidal anti-inflammatory drugs PCA : Principle component analysis PLS-DA : Partial least squares discriminant analysis POC : Proof-of-concept VIP : Variable importance in projection
- Downloaded 957 times
- Download rankings, all-time:
- Site-wide: 28,397
- In microbiology: 1,664
- Year to date:
- Site-wide: 113,084
- Since beginning of last month:
- Site-wide: 127,563
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!